Edgar Filing: BIOSPECIFICS TECHNOLOGIES CORP - Form 4

BIOSPECIFICS TECHNOLOGIES CORP

Form 4

October 08, 2008

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB Number:

OMB APPROVAL

3235-0287

Expires:

January 31, 2005

0.5

Estimated average

burden hours per

response...

if no longer subject to Section 16. Form 4 or Form 5

obligations

may continue.

See Instruction

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * RA CAPITAL MANAGEMENT, LLC

2. Issuer Name and Ticker or Trading Symbol

5. Relationship of Reporting Person(s) to

Issuer

BIOSPECIFICS TECHNOLOGIES CORP [BSTC]

(Check all applicable)

(Last)

(First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year)

Director X__ 10% Owner _ Other (specify Officer (give title below)

C/O RA CAPITAL MANAGEMENT, LLC, 800

BOYLSTON STREET, SUITE 1500

4. If Amendment, Date Original

6. Individual or Joint/Group Filing(Check

Applicable Line)

(Street)

Filed(Month/Day/Year)

10/06/2008

Form filed by One Reporting Person X_ Form filed by More than One Reporting

Person

BOSTON, MA 02199

(City)	(State)	Zip) Table	e I - Non-D	erivative	Secur	ities Acqu	uired, Disposed o	f, or Beneficial	ly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactio Code (Instr. 8)	4. Securi on(A) or Di (Instr. 3,	spose	d of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/06/2008		P	4,600 (1)	A	\$ 16	634,144	I	see footnote
Common Stock	10/06/2008		P	400 (1)	A	\$ 15.6	634,544	I	see footnote (2)
Common Stock	10/06/2008		P	200 (1)	A	\$ 16.1	634,744	I	see footnote

(2)

Edgar Filing: BIOSPECIFICS TECHNOLOGIES CORP - Form 4

Common Stock	10/06/2008	P	200 (1) A	\$ 17	634,944	I	see footnote
Common Stock	10/06/2008	P	500 (1) A	\$ 16.73	635,444	I	see footnote (2)
Common Stock	10/07/2008	P	1,000 A	\$ 14.4	636,444 (3)	I	see footnote

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

(9-02)

9. Nu Deriv Secu Bene Own Follo Repo Trans (Insti

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5.	6. Date Exerc	cisable and	7. Titl	le and	8. Price of	ç
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transact	ionNumber	Expiration Da	ate	Amou	int of	Derivative]
Security	or Exercise		any	Code	of	(Month/Day/	Year)	Under	rlying	Security	,
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Derivative	e		Secur	ities	(Instr. 5)]
	Derivative				Securities			(Instr.	3 and 4)		(
	Security				Acquired						J
					(A) or						J
					Disposed						-
					of (D)						(
					(Instr. 3,						
					4, and 5)						
									Amount		
						Date	Expiration	·	or		
					Exe	•	Date	Title Number	Number		
									of		
				Code V	(A) (D)				Shares		

Deletionships

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
RA CAPITAL MANAGEMENT, LLC C/O RA CAPITAL MANAGEMENT, LLC 800 BOYLSTON STREET, SUITE 1500 BOSTON, MA 02199		X				
ALDRICH RICHARD C/O RA CAPITAL MANAGEMENT, LLC 800 BOYLSTON STREET, SUITE 1500 BOSTON, MA 02199		X				
		X				

Reporting Owners 2

Edgar Filing: BIOSPECIFICS TECHNOLOGIES CORP - Form 4

X

X

Kolchinsky Peter C/O RA CAPITAL MANAGEMENT, LLC 800 BOYLSTON STREET, SUITE 1500 BOSTON, MA 02199

RA Capital Biotech Fund LP

C/O RA CAPITAL MANAGEMENT, LLC 800 BOYLSTON STREET, SUITE 1500

BOSTON, MA 02199

RA Capital Biotech Fund II, L.P.

C/O RA CAPITAL MANAGEMENT, LLC 800 BOYLSTON STREET, SUITE 1500

BOSTON, MA 02199

Signatures

Peter Kolchinsky, Manager of RA Capital Management, LLC 10/08/2008

**Signature of Reporting Person Date

Richard H. Aldrich 10/08/2008

**Signature of Reporting Person Date

Peter Kolchinsky 10/08/2008

**Signature of Reporting Person Date

Peter Kolchinsky, Manager of RA Capital Management, LLC, the General Partner of RA Capital Healthcare Fund, L.P.

**Signature of Reporting Person Date

Peter Kolchinsky, Manager of RA Capital Management, LLC, the General Partner of RA Capital Healthcare Fund II, L.P.

10/08/2008

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The acquired shares are divided between RA Capital Healthcare Fund, L.P. ("Fund I") and RA Capital Healthcare Fund II, L.P. ("Fund I") in a ratio of 98.90/1.10.
 - RA Capital Management, LLC (the "General Partner") is the general partner of both Fund I and Fund II, and Richard H. Aldrich and
- (2) Peter Kolchinsky are the sole managers of the General Partner. Each of the Reporting Persons disclaims his or its beneficial ownership of any shares of the above named Issuer reported herein, except to the extent of his or its pecuniary interest therein.
- (3) This number represents 628,515 shares held by Fund I and 7,929 shares held by Fund II.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3